• Corpus ID: 71022930

Temps de doublement du PSA et son calcul

@article{Ruffion2005TempsDD,
  title={Temps de doublement du PSA et son calcul},
  author={A. Ruffion and Xavier R{\'e}billard and François Grima},
  journal={Progres En Urologie},
  year={2005},
  volume={15},
  pages={1035-1041}
}
Le Prostate Specific Antigen (PSA) est aujourd'hui le meilleur marqueur du cancer de la prostate, bien qu'il soit peu specifique de cette pathologie. L'utilisation de sa cinetique, en plus de sa valeur absolue parait intellectuellement tres seduisante dans un grand nombre de situations cliniques. A partir d'une revue de la litterature, nous rapportons les differents moyens d'etudier cette cinetique, en insistant sur le plus abouti : le temps de doublement du PSA. Apres avoir precise les… 

Regain d’intérêt pour la grenade, un fruit majestueux aux multiples propriétés

TLDR
Pomegranate is proposed as an adjunct in the treatment of certain diseases such as cardiovascular disease, diabetes and some cancers particularly that of the prostate, which has found an unprecedented upsurge of interest among both scientists and consumers.

Cinétique du PSA après prostatectomie totale PSA kinetics after total prostatectomy

The prostate specific antigen (PSA) is the best marker of the pros- tate cancer today although not very specific of this pathology. The dynamic interpretation of this marker always has to prevail

Using the SAEM algorithm for mechanistic joint models characterizing the relationship between nonlinear PSA kinetics and survival in prostate cancer patients

TLDR
A novel development of the Stochastic‐Approximation Expectation Maximization algorithm is used that allows joint models defined by nonlinear mixed‐effect models to be defined and suggests that mechanistic joint models could constitute a relevant approach to evaluate the efficacy of treatment and to improve the prediction of survival in patients.

References

SHOWING 1-10 OF 108 REFERENCES

Prostate-specific antigen doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy: a novel analysis.

TLDR
The rate of increase in PSA appears to be similar in the two groups after year 2, which suggests the rate of growth of cancers that recur after radiation therapy and radical prostatectomy is similar.

Natural history of changes in prostate specific antigen in early stage prostate cancer.

PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.

TLDR
The PSADT appears to be an important predictor of SP and also of any clinical progression (local or systemic) in men who have undergone radical prostatectomy and have postoperative biochemical failure and to identify predictors of clinical disease progression.

Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy.

TLDR
A biochemical response can be expected in the majority of patients within 3 years of receiving SRT, and PSADT is an independent predictor of biochemical and clinical disease recurrence following SRT.

Analysis of PSA velocity in 1666 healthy subjects undergoing total PSA determination at two consecutive screening rounds.

TLDR
A reliable estimate of PSAV is provided based on a large unbiased population sample and might be of value as an indicator for diagnostic assessment and random sextant biopsy in a screening setting.
...